Background: Serum amyloid A4 (SAA4) is an apolipoprotein that is in the SAA fam-
Essentials
• Plasma SAA4 levels were higher in patients with venous thrombosis.
• Elevated plasma constitutive SAA4 levels were linked to VTE independent of acute-phase SAA.
• Recombinant SAA4 was procoagulant in plasma factor Xa-1-stage clotting assays.
• Recombinant SAA4 promoted thrombin generation in purified prothrombinase assays.
| INTRODUCTION
Venous thrombosis and arterial cardiovascular disease were traditionally regarded as separate diseases. However, several studies have shown that patients with venous thromboembolism (VTE) have an increased risk of subsequent arterial disease. [1] [2] [3] [4] [5] [6] An association between VTE and risk factors for atherosclerotic vascular diseases is emerging and may help identifying new risk factors for VTE.
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This is the case of the association between lipoprotein levels and VTE that could be explained by common factors that are a consequence of lipid properties on the hemostasis balance and inflammation. 8 These factors include changes in levels of C-reactive protein and acute-phase serum amyloid A (SAA). 9 Recent studies show that acute-phase SAA can directly bind to fibrin and affect coagulation by promoting amyloid formation in fibrin.
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The SAA gene family has 4 members. SAAs can be divided into 2 subgroups, comprising acute-phase SAA1 and SAA2 associated with HDL and inflammation in the first subgroup 11 and SAA4 in the second subgroup. SAA3 is expressed in mice but not in humans. SAA1 and SAA2 are acute-phase apolipoproteins that may rise >100-fold in acute inflammation. [12] [13] [14] Constitutive SAA4, where "constitutive" denotes its level is not subject to remarkable alterations, 15, 16 is linked to a certain group of HDL particles (HDL 3 ). 17 More recent studies have identified a minor portion of SAA4 that is in the LDL and VLDL subfractions. 18, 19 SAA4 comprises >90% of the total serum SAA proteins 17 in the absence of inflammatory pathologies with a serum concentration of 42 to 86 µg/mL, which is high in comparison with basal acute-phase SAA (SAA1 plus SAA2) levels (average, 1-2 µg/ mL). 9,12,13 SAA4 expression is implicated during inflammation including atherosclerosis; notably, SAA4 lacks expression in normal arteries but is expressed in carotid lesions. 20 Thus, SAA4 is a histologic and serologic biomarker for atheromatous lesions. 21, 22 However, the specific physiological role of SAA4 has not been well defined.
12,13
Previously, we reported that increased levels of acute-phase SAA is associated with the risk of VTE. 9 However, constitutive SAA4, which is present in plasma at much higher concentrations than acute-phase SAA, has not yet been investigated for its association with VTE. The absence of any specific studies of SAA4 related to hemostasis led us to measure SAA4 plasma levels in a cohort of VTE subjects and to assay recombinant purified SAA4 in coagulation assays. This study suggests an association between high levels of plasma SAA4 and increased risk of VTE independent of acute-phase SAA and suggests that the procoagulant properties of SAA4 might be involved in the pathology for development of VTE.
| MATERIALS AND METHODS

| Materials
Human factor Va (FVa), factor Xa (FXa), Gla-domainless (DG)-factor Xa, and biotinylated factor Xa were purchased from Hematologic 
| VTE patient and control groups
The Scripps Venous Thrombosis Registry is a case-control study of risk factors for VTE.
Plasma samples were drawn from 113 VTE patients and 113 ageand sex-matched subjects. Table 1 .
| ELISA measurements of total SAA4 in plasma
ELISA measurements of total SAA4 were performed using a commercial kit from Aviscera Bioscience Inc (Santa Clara, CA, USA).
| Immunoblotting of SAA4 isomers in plasma
Plasma was diluted 1/50 in Tris-buffered saline buffer, and 
| Clotting assays
For FXa 1-stage clotting assays, citrated plasma was incubated with FXa (34 nmol/L) and varying concentrations of rat SAA4. Clotting was initiated by adding 30 mM CaCl 2 .
| Prothrombin activation assays
Prothrombin activation by FXa/FVa or Gla-domainless-FXa/FVa were assayed in the presence of various concentrations of rat SAA4. Prothrombin (0.76 μmol/L final) activation was also assayed in the absence of FVa and phospholipid by adding purified FXa (0.125 nmol/L final) plus or minus varying concentrations of SAA4 preparations using a 120-minute incubation. 
| Statistical analysis
| RESULTS AND DISCUSSION
Here, we discovered that the median plasma SAA4 level determined by SAA4 ELISA was higher in VTE cases than in matched controls (48.1 vs. 38.4 µg/mL; P < .001; Figure 1A ). Elevated plasma SAA4 levels, defined as above the 90th percentile of con- (Table 3) . Among them, HDL particles levels were correlated with SAA4. However, the association of elevated plasma SAA4 levels above the 90th, 75th and 67th percentile of controls with VTE occurrence remained significant after adjustment for HDL particle levels ( Table 2 , Model II). When the association of SAA4 with acute SAA levels (SAA1 + SAA2) and another acute inflammatory marker, C-reactive protein (CRP), were evaluated, plasma SAA4 levels positively correlated with acutephase SAA and CRP levels (r = .28, P < .0001; and r = .15, P = .023, respectively). However, when plasma levels of acute-phase SAA and CRP were included as covariates, the association of elevated plasma SAA4 with VTE occurrence remained significant (Table 2, Models III-V). These findings suggest that elevated plasma SAA4 is indeed associated with increased occurrence of VTE independent of these other parameters.
Total plasma SAA4 levels determined by ELISA is composed of 2 isoforms because SAA4 in plasma is partially glycosylated at Asn76 resulting in a 19-kDa glycosylated monomer in addition to the 14-kDa nonglycosylated monomer. 13 Hence, quantitative immunoblotting was used to measure each isoform in VTE cases and controls.
Plasma median levels of both the 14-kDa isoform ( Figure 1B ) and the 19-kDa SAA4 isoform ( Figure 1C) were elevated in VTE patients compared to controls (120.2% vs. 100%, P < .001; and 119.4% vs. 100%, P < .01, respectively).
In recent years, studies have identified minor abundance plasma lipids and apolipoproteins that may influence hemostasis or cardiovascular events. 24, 25 We previously found that acute-phase SAA measured by ELISA, that is, SAA1 and SAA2, was elevated in VTE patients. Here, we studied constitutive SAA4, the other member of the human SAA family, which contains 112 residues and shares substantial homology with mature SAA1, which contains 104 residues. Previously, nothing was known about SAA4's association with blood coagulation.
To assess its procoagulant activity, recombinant 14-kDa monomer SAA4 made in E. coli was studied in various coagulation assays.
Recombinant SAA4 dose-dependently shortened the FXa-1-stage clotting time from 320 seconds to 55 seconds ( Figure 2A One limitation of this study is the modest number of VTE patients (113 patients). Replication studies and further analyses are needed to confirm our discovery and to determine whether SAA4 levels might be of value in predicting VTE. The timing of a blood draw in relation to the clinical event can raise an issue of validity of conclusions, as all blood samples came long after the clinical event.
Some plasmas were obtained >5 years after the clinical presentation.
However, subgrouping of the Scripps patients with VTE was made based on time since the clinical event (ie, <1 year, 1-3 years, >3 years), and the SAA4 median values were not different between subgroups (Table 3 ). The use of warfarin at the time of blood collection might be a potential issue, as the Scripps VTE registry included some warfarin users among VTE cases. However, there was no difference in plasma levels of SAA4 between warfarin users and nonusers, suggesting that warfarin use did not affect the association of elevated SAA4
TA B L E 2
Odds ratio for VTE based on elevated plasma SAA4 level above 90th, 75th, and 67th percentile of controls without and with adjustments
Percentile of SAA4
Odds ratio (95% CI) Note: Logistic regression was used to evaluate the association between elevated plasma SAA4 levels and VTE occurrence using STATA (StataCorp LLC, College Station, TX, USA) and odds ratio (95% confidence interval) for VTE based on elevated plasma SAA4 levels of VTE patients above the 90th percentile of controls are shown.
The value for 90th, 75th, and 67th percentile of plasma SAA4 in normal subjects served as the reference group. Models II to V were adjusted by variables indicated in the Note: Subgroup analysis for plasma SAA4 levels by gender, years at blood sampling from the VTE event, pulmonary embolism occurrence, carrier of factor V Leiden or prothrombin G20210A, warfarin use, or hormone use were performed to test if these are influences on plasma SAA4 levels.
The median values for each subgroup and their difference (P values) are shown. The SAA4 levels were also analyzed for correlation with age, BMI, lipoprotein particles (VLDL, LDL, and HDL particles), CRP and acutephase SAA1 + SAA2; and the Spearman r and P values are shown. N = 113 subjects, except data for CRP value for 1 VTE subject was missing.
with VTE occurrence (Table 3) . VTE patients were <55 years old at first event. The retrospective-based analysis of antigen levels from these studies does not distinguish causality from coincidence, but the procoagulant properties of SAA4 does provide some reasonable degree of likelihood for potential prothrombotic actions of SAA4.
Given that the patients were mainly Caucasians, the findings here remain to be evaluated in other racial groups.
In summary, these results show that elevated monomeric plasma levels of SAA4 are associated with VTE in adults <55 years old and that SAA4 itself is a potential enhancer of thrombin generation in plasma. These results support the hypothesis that SAA4 may act as a prothrombotic agent in vivo. In vivo proof-of-concept studies of SAA4's prothrombotic property are warranted, and if they were very successful, then reagents targeting SAA4 might become potential drug candidates.
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